---
title: "Acrivon Therapeutics, Inc. (ACRV.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ACRV.US.md"
symbol: "ACRV.US"
name: "Acrivon Therapeutics, Inc."
industry: "Biotechnology"
datetime: "2026-05-20T07:02:11.046Z"
locales:
  - [en](https://longbridge.com/en/quote/ACRV.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ACRV.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ACRV.US.md)
---

# Acrivon Therapeutics, Inc. (ACRV.US)

## Company Overview

Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 for the treatment of patients with endometrial and platinum-resistant ovarian cancer, and SCCs, such as SCCHN and anal cancer. The company is also developing ACR-2316, a dual WEE1 and PKMYT1 inhibitor small molecule candidate; and a preclinical stage AP3-and co-crystallography-based preclinical cell cycle program.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [acrivon.com](https://acrivon.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.89 | 173 | - | - | - |
| PB | 0.72 | 63 | 0.57 | 0.41 | 0.26 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-15T04:00:00.000Z

Total Analysts: **8**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 5 | 63% |
| Overweight | 3 | 38% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 1.60 |
| Highest Target | 19.00 |
| Lowest Target | 7.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/ACRV.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/ACRV.US/norm.md)
- [Related News](https://longbridge.com/en/quote/ACRV.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/ACRV.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**